A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE OF IDELALISIB PLUS RITUXIMAB OR BENDAMUSTINE PLUS RITUXIMAB IN BTK INHIBITOR PRETREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-321)
- Registry ID
- LOXO-BTK-20020 (J2N-OX-JZNN)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- LOXO ONCOLOGY INC
- Start date
- 2024-03-06
- Last update
- 2021-03-18
Conditions
- SMALL LYMPHOCYTIC LYMPHOMA
- CHRONIC LYMPHOCYTIC LEUKEMIA
Related clinical trials
- A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE, STUDY OF SUROVATAMIG AS CONSOLIDATION THERAPY VERSUS OBSERVATION AFTER FIRST-LINE INDUCTION THERAPY IN PARTICIPANTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WITH UNMUTATED IGHV (SOUNDTRACK-C1)
- AN OPEN-LABEL, PHASE 1/2 STUDY OF JCAR017 IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
- A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY
OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC
LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY
RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR
- A PHASE 3, RANDOMIZED STUDY TO COMPARE NEMTABRUTINIB VERSUS COMPARATOR (INVESTIGATOR'S CHOICE OF IBRUTINIB OR ACALABRUTINIB) IN PARTICIPANTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BELLWAVE-011)
- A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF SONROTOCLAX (BGB-11417) PLUS
ZANUBRUTINIB (BGB-3111) COMPARED WITH VENETOCLAX PLUS OBINUTUZUMAB IN
PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
- MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
View on source registry